Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Activists: Venezuela released just nine prisoners despite promise - 2Horses really can smell our fear, new study finds
- 3Get Cooking: 15 Speedy and Heavenly Recipes for Occupied Individuals
- 4A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns
- 5Monetary Wellness: Planning Tips for Independence from the rat race
- Tesla plans to expand production at German car plant
- More parents refusing this shot that prevents serious bleeding at birth
- The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- Poland open to German troops to help secure Ukraine ceasefire
- World leaders, rights groups react to COP30 climate deal
- Raw oysters linked to ongoing salmonella outbreak infecting 64 across 22 states: CDC
- 5 Great Crossover Vehicles For Eco-friendliness In 2024
- Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
- Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say
